(Q37686645)

22 August 2017

1 reference

title

5 Long-term acromegaly and associated cardiovascular complications: a case-based review (English)

1 reference

22 August 2017

1

Annamaria Colao

1 reference

22 August 2017

publication date

1 December 2009

1 reference

Best Practice and Research: Clinical Endocrinology and Metabolism

22 August 2017

published in

1 reference

22 August 2017

volume

23 Suppl 1

1 reference

22 August 2017

page(s)

S31-8

1 reference

Medical progress: Acromegaly

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Guidelines for acromegaly management: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Acromegaly and cancer: not a problem?

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

The GH-IGF-I axis and the cardiovascular system: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Insulin-like growth factor I and its binding proteins in the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Insulin-like growth factor I retards apoptotic signaling induced by ethanol in cardiomyocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

The effect of insulin-like growth factor-1 on adult rat cardiac contractility

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Systemic complications of acromegaly: epidemiology, pathogenesis, and management

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

The insulin-like growth factor axis: A review of atherosclerosis and restenosis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Serum insulin-like growth factor binding protein-2 levels as an indicator of functional ability in elderly men

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Cardiovascular function in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Determinants of clinical outcome and survival in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Acromegaly: an epidemiological study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Acromegaly and the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months

1 reference

https://api.crossref.org/works/10.1016%2FS1521-690X%2809%2970006-5

7 January 2021

10.1016/S1521-690X(09)70006-5

Identifiers

DOI

1 reference

22 August 2017

1 reference